

Grifols receives SBTi approval for its near-term science-based emission reduction targets

- *The company's commitments to reduce both direct and indirect emissions of greenhouse gases align with the Paris Agreement's goal to limit the planet's warming to 1.5 degrees Celsius this century*
- *Approved targets include a 42% decrease in scope 1 and 2 emissions by 2030 from Grifols' 2022 baseline, as well as a 25% reduction in scope 3 gases from purchased goods and services over the same time*
- *The SBTi-endorsed targets complement Grifols' previously stated commitments to achieve a more sustainable earth in alignment with the United Nations 2030 Agenda for Sustainable Development*

Barcelona, Spain, Oct. 24, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that its near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi), further underscoring the company's commitment to a healthier, greener and more sustainable planet.

The targets cover essentially all Grifols greenhouse gas (GHG) emissions from direct and indirect operations. These include:

- **Scope 1 and 2 GHG emissions:**

Grifols commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2022 base year (the target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks).
- **Scope 3 GHG emissions:**

Grifols commits to reduce absolute scope 3 GHG emissions from purchased goods and services, capital goods, fuel -and energy-related activities, and upstream transportation and distribution 25% within the same timeframe.

The science-based targets align with the United Nations Climate Conference-sponsored Paris Agreement, which in 2015 established a goal of keeping global temperatures from rising more than 1.5 degrees Celsius this century from preindustrial levels.

Grifols is also aligned with the United Nations 2030 Agenda for Sustainable Development, for which the company has developed its own goals to be completed by the end of the

GRIFOLS

decade that feature 30 ambitious, concrete and measurable commitments. These include reducing energy consumption and greenhouse emissions, increasing energy use from renewable sources, applying circular economy measures and protecting biodiversity.

With the SBTi-endorsed commitment, Grifols, recognized as one of the most sustainable companies in the world, reinforces the environmental pillar of its sustainability strategy and continues to advance on its broader sustainability roadmap.

“Validation of our science-based emission-reduction targets demonstrates Grifols’ firm commitment to taking specific and measurable actions to source, manufacture and consume more responsibly and sustainably as part of our broad-based initiatives to achieve a low-carbon society and a healthier world,” said Daniel Fleta, Grifols Chief Industrial Services Officer.

The SBTi is a corporate climate action organization that develops standards, tools and guidance enabling company GHG emissions-reduction targets in line with what is needed to control global warming and reach net-zero by 2050 at the latest. SBTi is incorporated as a charity, with a subsidiary that will host its target validation services. SBTi partners are Carbon Disclosure Project (CDP), the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (Tel. +34 659 572 185)

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez (Tel. + 34 659 572 185)

Borja_gomez@duomocomunicacion.com

Investors

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals. Grifols is

GRIFOLS

focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.